The Patent Finder

Bio-Thera Solutions, Ltd.

15 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Apr 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Oct 19, 2027
    The maintenance fee for Compounds and Methods for the Treatment of Egfr Positive Diseases (US 9,314,536) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,498,410Bifunctional Variants of Recombinant Tissue-Type Plasminogen Activator with Platelet Aggregation Inhibitory Activity
In force
 · High confidence
In forceHigh confidence
US 8,877,706Maytansinoid Derivatives
In force
 · High confidence
In forceHigh confidence
US 8,889,855Preparation of Maytansinoid Esters
In force
 · High confidence
In forceHigh confidence
US 9,314,536Compounds and Methods for the Treatment of Egfr Positive Diseases
In force
 · High confidence
In forceHigh confidence
US 9,345,786Maytansinoid Derivatives
In force
 · High confidence
In forceHigh confidence
US 9,737,616Compounds and Methods for the Treatment of Erb B2/NEU Positive Diseases
In force
 · Medium confidence
In forceMedium confidence
US 9,567,403Bispecific Antibodies Which Bind Egfr and VEGF
In force
 · High confidence
In forceHigh confidence
US 11,505,609Recombinant Antibody Having Unique Glycan Profile Produced by Cho Host Cell with Edited Genome and Preparation Method Thereof
In force
 · High confidence
In forceHigh confidence
US 11,192,954Compounds and methods for the treatment of TROP2 positive diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,679,895Recombinant Antibody Having Unique Glycan Profile Produced by Cho Host Cell with Edited Genome and Preparation Method Thereof
In force
 · High confidence
In forceHigh confidence
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
Also on record, not counted in the 15: 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

16 pending · 2 abandoned · 10 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited